<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04792723</url>
  </required_header>
  <id_info>
    <org_study_id>VG-BABE-19-01</org_study_id>
    <nct_id>NCT04792723</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic and Pharmacodynamic Study of a Novel Sublingual Aspirin Tablet</brief_title>
  <official_title>Pharmacokinetic and Pharmacodynamic Study of a Novel Sublingual Aspirin Tablet Compared to Conventional Oral Aspirin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vita Green Health Products Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vita Green Health Products Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to compare the pharmacokinetics and pharmacodynamics of a new&#xD;
      sublingual formulation of aspirin with that of oral aspirin when administered to healthy&#xD;
      volunteers under fasting conditions. The test product is sublingual aspirin 80 mg&#xD;
      manufactured by Vita Green Health Products Co. Ltd, Hong Kong and the reference product is&#xD;
      oral aspirin 80mg tablet manufactured by Synco (HK) Ltd, Hong Kong.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 5, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>single-dose, two-treatment, two-period, two-sequence, randomized, crossover design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma-concentration time data of salicylic acid</measure>
    <time_frame>pre dose and up to 24 hour post dose</time_frame>
    <description>area under the plasma concentration-time curve from time zero to last measurable concentration time point for sublingual versus oral aspirin 80mg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration of salicylic acid</measure>
    <time_frame>pre dose and up to 24 hour post dose</time_frame>
    <description>Peak plasma concentration for sublingual versus oral aspirin 80mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach peak plasma concentration of salicylic acid</measure>
    <time_frame>pre dose and up to 24 hour post dose</time_frame>
    <description>Tmax of sublingual versus oral aspirin 80mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal phase elimination rate constant of salicylic acid</measure>
    <time_frame>pre dose and up to 24 hour post dose</time_frame>
    <description>Terminal phase elimination rate constant of sublingual versus oral aspirin 80mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life of salicylic acid</measure>
    <time_frame>pre dose and up to 24 hour post dose</time_frame>
    <description>Terminal elimination half-life of sublingual versus oral aspirin 80mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration time data of thromboxane B2</measure>
    <time_frame>pre dose and up to 24 hour post dose</time_frame>
    <description>Area under the curve for sublingual versus oral aspirin 80mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet aggregation by impedance aggregometry</measure>
    <time_frame>pre dose and up to 360 minutes post dose</time_frame>
    <description>Differences in platelet aggregation with sublingual versus oral aspirin 80mg</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Healthy volunteer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual or oral aspirin 80mg tablet, single dose, two-treatment, two-period, two-sequence, randomized, crossover design, with washout 1-2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual aspirin</intervention_name>
    <description>Vita Green Health Products sublingual aspirin 80 mg tablet</description>
    <arm_group_label>Healthy volunteer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral aspirin</intervention_name>
    <description>Synco (HK) oral aspirin 80mg tablet</description>
    <arm_group_label>Healthy volunteer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male, 18 to 55 years of age&#xD;
&#xD;
          2. Body mass index between 18-27kg/m2&#xD;
&#xD;
          3. Accessible vein for blood sampling&#xD;
&#xD;
          4. High probability for compliance and completion of the study&#xD;
&#xD;
          5. No significant abnormalities in general physical examination&#xD;
&#xD;
          6. Subjects must agree to take effective contraceptive methods to prevent his partner&#xD;
             pregnant during the time of first dose of study medication until one week of last dose&#xD;
             administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of hepatic, renal, biliary, cardiovascular, gastrointestinal, haematological&#xD;
             and other chronic and acute diseases within 3 months prior to screening&#xD;
&#xD;
          2. Clinically relevant abnormality in physical examination, ECG evaluation, urine test,&#xD;
             blood chemistry or haematological test at the discretion of the investigator&#xD;
&#xD;
          3. Positive results for hepatitis B at screening&#xD;
&#xD;
          4. Moderate smoker (on average more than 2 cigarettes a day within 1 month prior to the&#xD;
             start of first dosing)&#xD;
&#xD;
          5. Moderate consumption of alcohol (on average more than one drink per day within 1 month&#xD;
             prior to start of first dosing)&#xD;
&#xD;
          6. Blood donation of more than 350 ml within 4 weeks prior to start of first drug dosing&#xD;
&#xD;
          7. Treatment of aspirin within 4 weeks before first dosing&#xD;
&#xD;
          8. Volunteer in any other clinical drug study within 2 months prior to start of first&#xD;
             dosing&#xD;
&#xD;
          9. Hypersensitivity to aspirin or other drug in its class&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elaine Chow</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rolley Lee</last_name>
    <phone>+852 29035983</phone>
    <email>rolley.lee@vitagreen.com</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. Elaine Chow</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

